{"id":"NCT03614663","sponsor":"Zynerba Pharmaceuticals, Inc.","briefTitle":"Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-06-12","primaryCompletion":"2020-06-14","completion":"2020-06-14","firstPosted":"2018-08-03","resultsPosted":"2022-06-16","lastUpdate":"2022-07-06"},"enrollment":212,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fragile X Syndrome"],"interventions":[{"type":"DRUG","name":"ZYN002 - Cannabidiol Transdermal Gel","otherNames":[]},{"type":"OTHER","name":"Placebo Transdermal Gel","otherNames":["Placebo Comparator","Matching Placebo"]}],"arms":[{"label":"ZYN002 - Cannabidiol transdermal gel","type":"EXPERIMENTAL"},{"label":"Placebo transdermal gel","type":"PLACEBO_COMPARATOR"}],"summary":"This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome (FXS). Eligible participants will then participate in up to a 14 week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \\< 18 years, will be eligible to participate.","primaryOutcome":{"measure":"Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Social Avoidance Subscale - Full Analysis Set","timeFrame":"Change from Baseline to end of treatment (Week 12)","effectByArm":[{"arm":"ZYN002 - Cannabidiol Transdermal Gel","deltaMin":-2.68,"sd":0.31},{"arm":"Placebo","deltaMin":-2.29,"sd":0.318}],"pValues":[{"comp":"OG000 vs OG001","p":"0.321"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":14},"locations":{"siteCount":21,"countries":["United States","Australia","New Zealand"]},"refs":{"pmids":["36434514","33395098"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["upper respiratory tract infection","nasopharyngitis","vomiting","pyrexia","application site pain"]}}